



1617

Patent Application  
Attorney Docket No. PC110-HAGLK

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, Washington, D.C. 20231 on this 9th day of September, 2002.

By \_\_\_\_\_

*Deanna Miller*

(Signature of person mailing)

Deanna Miller

(Typed or printed name of person)

2002

ED

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF: Thomas A. Vendola

APPLICATION NO.: 10/057,171

: Examiner: San Ming R. Hui

FILING DATE: January 25, 2002

: Group Art Unit: 1617

TITLE: PHARMACEUTICAL DOSAGE FORMS  
WITH ENHANCED COHESIVE AND  
COMPRESSIBILITY PROPERTIES

Hon. Commissioner for Patents  
Washington, D.C. 20231

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.**

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820, which lists the references, cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.204(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Applicant believes that no fee is necessary in accordance with 37 C.F.R. §1.97(c) because each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to filing the Information Disclosure Statement. The art cited in this Supplemental Information Disclosure was cited in a communication for the European Patent Office dated September 28, 2001.

Respectfully submitted,

Date: Sept. 9 2002

*Gabriel L. Kleiman*  
Gabriel L. Kleiman  
Attorney for Applicant(s)  
Reg. No. 40,681

Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-0041



RECEIVED  
SEP 17 2002  
TECH CENTER 10 2000

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>									ATTY. DOCKET NO. PC11014ACJG	SERIAL NO. 10/057,171				
APPLICANT Thomas A. Vendola														
FILING DATE January 25, 2002									GROUP	1617				
<b>U.S. PATENT DOCUMENTS</b>														
EXAMINER INITIAL		DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US	5	9	5	8	4	5	5	09/28/99	Roser et al.	424	489		
<b>FOREIGN PATENT DOCUMENTS</b>														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	WO	0	1	8	9	4	8	5	29.11.01	International	A61K	9/46	YES	NO
	EP	0	9	1	4	8	1	8	12.05.99	Europe	A61K	9/20		
	EP	0	9	6	0	6	2	1	01.12.99	Europe	A61K	31/505		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
EXAMINER				DATE CONSIDERED										
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>														